The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 938 GLP-1 Medications articles
At the Oscars 2026 red carpet, an overwhelming uniformity of extremely slender bodies and sunken cheeks dominated, raising questions about Ozempic and GLP-1 agonists. Celebrities like Demi Moore, Emma Stone, and Oprah Winfrey appeared dramatically thinner, contrasting the body positivity era. Is Hollywood reverting to 'heroin chic' aesthetics?
Revolutionary GLP-1 medications like Ozempic are helping millions shed pounds quickly, but a new study shows significant muscle loss is a downside. Experts warn that up to 40% of weight lost can be lean tissue, especially with rapid drops. Here's how to protect your muscle while benefiting from these drugs.
Stopping Ozempic can lead to full weight regain in about 1.7 years, plus reversal of cardiovascular and metabolic benefits, warns a major BMJ review. Nearly 50% of users discontinue within a year due to side effects and high costs. Doctors urge consulting before quitting to protect your health gains.
South African DJ Shimza set the record straight on Podcast and Chill, firmly denying rumors that his impressive weight loss came from Ozempic or that he profits from government tenders. With his partner Athi Geleba in a high-profile Presidency position, speculation ran wild—but Shimza insists he earns his money through hard work. This candid interview sheds light on celebrity health rumors and tender controversies.
Side-by-side photos of Vanessa Williams highlight her 'Ozempic face' transformation, marked by wrinkles and an 'Ozempic neck' after using Mounjaro for menopause-related weight gain. The first Black Miss America calls it a 'game-changer' at age 60. A plastic surgeon details how GLP-1 drugs affect facial fat and skin health.
Structure Therapeutics announced impressive Phase 2 results for its daily obesity pill, with patients losing about 16% of their body weight compared to placebo after 44 weeks. This positions the company to challenge leaders like Eli Lilly and Novo Nordisk in the race for effective oral GLP-1 therapies. Discover the details and implications for obesity treatment.
This awards season, Hollywood red carpets showcase pin-thin silhouettes from Emma Stone to Jenna Ortega, fueled by Ozempic microdosing. Stylists fear stars are unaware of their extreme thinness, while nutritionists spot muscle wasting and malnutrition signs. As body positivity fades, insiders reveal the pressure and health toll.
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
